Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects
Why the study?
Does low-dose oral aspirin selectively and cumulatively inhibit platelet thromboxane production without affecting renal prostaglandin synthesis in healthy subjects?
Population
46 healthy subjects (men and women)
Comparison
Oral aspirin vs Baseline values (before aspirin administration)
Design
Cohort
Follow-up
1 month
Authors
Discussion
Loading...
Member takes
Implication
Supports selective low-dose aspirin regimens in healthy subjects; leaves open translation to patients with cardiovascular disease.
Structured PICO
Does low-dose oral aspirin selectively and cumulatively inhibit platelet thromboxane production without affecting renal prostaglandin synthesis in healthy subjects?
P
Population
46 healthy subjects (men and women)
I
Intervention
Oral aspirin (single doses of 6-100 mg, or a daily dose of 0.45 mg/kg for 7 days up to 1 month)
C
Comparator
Baseline values (before aspirin administration)
O
Outcome
Serum thromboxane B2 (TXB2) levels after whole blood clotting and urinary excretion of PGE2, PGF2alpha, and 6-keto-PGF1alphasurrogate
Low-dose daily aspirin selectively and cumulatively inhibits platelet thromboxane production without suppressing renal prostaglandin synthesis in healthy subjects.
Cite This Study
Patrignani et al. (1982) studied this question.